Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-072272
Filing Date
2025-07-30
Accepted
2025-07-30 17:31:32
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9774
  Complete submission text file 0001104659-25-072272.txt   11535
Mailing Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305
Business Address 301 CARLSON PARKWAY SUITE 210 MINNEAPOLIS MN 55305 (763) 496-5454
DiaMedica Therapeutics Inc. (Subject) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90788 | Film No.: 251168338
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O EQT PARTNERS AB BOX 16509 STOCKHOLM V7 103 27
Business Address C/O EQT PARTNERS AB BOX 16509 STOCKHOLM V7 103 27 46 70 514 21 94
TomEnterprise AB (Filed by) CIK: 0001887435 (see all company filings)

EIN.: 000000000